Growth and Improved Profitability of the Metabolome Analysis Business

「Sales from the life science research support services business declined substantially because of a decrease in large projects in the domestic academia sector and a significant decline in overseas sales due to lower overall market demand, among other factors, to ¥930.832 million, down 18.6% from the previous consolidated fiscal year.」

「Revenue for the interim consolidated accounting period decreased to ¥659.216 million, down 3.7% year on year.」

「As a result, revenue for the segment as a whole was ¥527.801 million, up 2.1% year on year. In addition, concentrated investment in research and development for the “biomanufacturing” productivity improvement support service increased segment expenses, resulting in segment profit after allocation of corporate expenses of ¥76.052 million, down 19.6%.」

「As a result, revenue was ¥1,186.852 million, down 5.2% year on year. Segment profit after allocation of corporate expenses was ¥310.700 million, down 12.1%.」

「As a result, revenue was ¥963.363 million, down 7.9% year on year, and segment profit after allocation of corporate expenses was ¥299.387 million, down 19.8%.」

「As a result, revenue was ¥516.990 million, down 12.0% year on year, and segment profit after allocation of corporate expenses was ¥94.565 million, down 38.5%.」

「As a result, revenue was ¥221.257 million, down 13.5% year on year. In addition to lower revenue, higher cost of sales associated with the introduction of cutting-edge equipment and increased sales of partner services affected segment profit after allocation of corporate expenses, which was ¥3.900 million, down 89.9%.」

「For the Group as a whole, we believe progress has been made in transforming the business into one capable of generating sustainable earnings. While continuing necessary investments, we will promote initiatives aimed at sustainable earnings growth.」

「As a result, revenue was ¥1,045.761 million, up 3.8% year on year, and segment profit after allocation of corporate expenses was ¥373.253 million, up 4.1%.」

「In this business segment, high-sensitivity comprehensive analysis services remained firm both domestically and overseas, resulting in a substantial increase in sales, particularly in the academic sector. Efforts to reduce selling, general and administrative expenses also resulted in substantial increases in both revenue and profit.」

「Segment profit also increased substantially, in addition to higher revenue, due in part to significant reductions in selling, general and administrative expenses resulting from the closure of a European subsidiary, reaching ¥331.992 million, up 134.9% year on year.」

「In this business segment, orders remained strong across all fields, including academia, pharmaceuticals, food and chemicals. Orders from academia and pharmaceutical companies increased substantially, particularly due to expanded sales of high-sensitivity comprehensive analysis services and lipid analysis services, resulting in a substantial increase in domestic sales. As a result, revenue was ¥1,007.483 million, up 9.1% year on year, and segment profit was ¥358.589 million, up 101.6% year on year.」

「In this business segment, orders remained strong across all fields, including academia. In domestic sales, revenue from food and cosmetics companies increased substantially due to an increase in human studies. Sales to pharmaceutical companies also increased as a result of expanded sales of high-sensitivity comprehensive analysis services.」

「In this business segment, domestic sales in the academic sector were at about the same level as the previous year, but overall sales declined substantially due to the significant impact of delays in research and development in the food, cosmetics and other chemical fields.」

「As a result, the Metabolomics Business had an order backlog of ¥199.325 million at the end of the consolidated fiscal year, compared with ¥321.950 million at the end of the previous consolidated fiscal year.」

「As a result, revenue was ¥923.697 million, down 6.7% year on year, and segment profit was ¥391.422 million, down 21.0%.」

「In this business segment, sales activities centered on the use of the web resulted in a substantial increase in sales in the domestic academic sector, while overseas sales also increased substantially in the U.S. pharmaceutical sector. As a result, revenue was ¥535.305 million, up 18.1% year on year, and segment profit was ¥181.437 million, up 42.2% year on year.」

「In this business segment, the Group conducted sales activities centred on the use of the Web. As a result, sales increased significantly in the domestic food sector and in the overseas US pharmaceutical sector. Consequently, revenue was ¥244.837 million, up 23.8% year on year, and segment profit was ¥60.608 million, up 91.3% year on year.」

「We believe that the transformation toward a business structure capable of generating a balanced level of earnings has progressed. While continuing necessary investments, we will promote initiatives to maximize earnings, particularly in the Metabolomics Business.」

「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to expand orders for large projects. As a result, sales increased across all fields compared with the corresponding period of the previous year, 1 July 2018 to 31 March 2019. The Group also reviewed its sales strategy and worked to strengthen its sales structure.」

「Meanwhile, the operating loss was ¥123.179 million due in part to business development for biomarker-related businesses and efforts to strengthen the business platform for further growth of the Metabolomics Business.」

「Meanwhile, the operating loss was ¥89.246 million due in part to business development for biomarker-related businesses and efforts to strengthen the business platform for further growth of the Metabolomics Business.」

「It is extremely important for the Metabolomics Business to achieve steady growth and make a sustained contribution to earnings by improving production processes such as analysis and measurement.」

「Meanwhile, due in part to research and development aimed at commercializing depression biomarkers and efforts to strengthen the business platform for further growth of the Metabolomics Business」

「Due in part to efforts to strengthen the business platform for further growth of the Metabolomics Business」

「The operating loss was ¥293.362 million, compared with an operating loss of ¥228.648 million in the same period of the previous year, due in part to research and development aimed at commercializing depression biomarkers and efforts to strengthen the business platform for further growth of the Metabolome Analysis Business.」

「The operating loss was ¥129.601 million, compared with an operating loss of ¥130.023 million in the same period of the previous year, due in part to efforts to strengthen the business platform for further growth of the Metabolome Analysis Business.」

「It is extremely important for the Metabolomics Business to achieve steady growth and make a sustained contribution to earnings by improving production processes such as analysis and measurement.」